1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Bayer Set To Sew Up HCC Market As RESORCE Hits Endpoint

 
• By Alexandra Shimmings

Top-line success for Bayer's trial of Stivarga in advanced liver cancer in patients who have progressed on its other therapy Nexavar gives the company an opportunity to dominate the market, but Stivarga's potential may be overshadowed by its drawbacks and looming competition.

Bayer HealthCare AG is poised to strengthen its hold on the liver cancer market after its multi-targeted anticancer Stivarga (regorafenib) met its primary endpoint in the Phase III RESORCE study testing it as a second-line treatment option for liver cancer patients whose disease has progressed after standard-of-care first-line therapy with the company's Nexavar (sorafenib).

Bayer plans to submit the data from RESORCE (regorafenib after sorafenib in patients with hepatocellular carcinoma) as the basis for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

 
• By Alaric DeArment

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By Kevin Grogan

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

In Brief: Sanofi Cements Support For Adagene

 
• By Kevin Grogan

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

In Vivo CAR-T Interest Grows With AbbVie Acquisition

 
• By Andrew McConaghie

Acquiring Capstan gives AbbVie a stake in two competing in vivo CAR-T delivery platforms, with the field's first readouts expected in 2026.

More from Therapy Areas

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 
• By Jessica Merrill

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

In Brief: Sanofi Cements Support For Adagene

 
• By Kevin Grogan

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

In Vivo CAR-T Interest Grows With AbbVie Acquisition

 
• By Andrew McConaghie

Acquiring Capstan gives AbbVie a stake in two competing in vivo CAR-T delivery platforms, with the field's first readouts expected in 2026.